Abstract
Metabolomics is a recently emerging member of the “omics” technologies. It aims at detecting and quantifying all detectable small molecules, the so-called metabolites, present in a biological sample. Because of the lower number of metabolites compared with the number of genes and proteins identified in genomics and proteomics approaches, data of metabolic studies are less complex and may therefore be more informative. Metabolomics may thus significantly contribute to our understanding of disease mechanisms. Autoimmune diseases are of growing clinical relevance, and due to the chronic nature of these diseases successful treatment is often challenging. In the past years, a variety of studies have been published about the metabolome of autoimmune diseases such as Crohn ’ s disease and rheumatoid arthritis. However, our understanding of the role of different metabolites in the pathogenesis of autoimmune diseases is still far from being complete.
Keywords: Autoimmunity, Crohn's disease, rheumatoid arthritis, metabolomics
Current Drug Discovery Technologies
Title: Metabolic Changes in Autoimmune Diseases
Volume: 6 Issue: 4
Author(s): Karsten Seeger
Affiliation:
Keywords: Autoimmunity, Crohn's disease, rheumatoid arthritis, metabolomics
Abstract: Metabolomics is a recently emerging member of the “omics” technologies. It aims at detecting and quantifying all detectable small molecules, the so-called metabolites, present in a biological sample. Because of the lower number of metabolites compared with the number of genes and proteins identified in genomics and proteomics approaches, data of metabolic studies are less complex and may therefore be more informative. Metabolomics may thus significantly contribute to our understanding of disease mechanisms. Autoimmune diseases are of growing clinical relevance, and due to the chronic nature of these diseases successful treatment is often challenging. In the past years, a variety of studies have been published about the metabolome of autoimmune diseases such as Crohn ’ s disease and rheumatoid arthritis. However, our understanding of the role of different metabolites in the pathogenesis of autoimmune diseases is still far from being complete.
Export Options
About this article
Cite this article as:
Seeger Karsten, Metabolic Changes in Autoimmune Diseases, Current Drug Discovery Technologies 2009; 6 (4) . https://dx.doi.org/10.2174/157016309789869074
DOI https://dx.doi.org/10.2174/157016309789869074 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Update on Intravenous Immunoglobulins (IVIg) Mechanisms of Action and Off- Label use in Autoimmune Diseases
Current Pharmaceutical Design Expression and Function of Cytokines and Chemokines in Neuropsychiatric Related Systemic Lupus Erythematosus
Current Rheumatology Reviews Dendritic Cells and Immunomodulation: Role in Health and Disease
Current Immunology Reviews (Discontinued) Current Status of Vitamin D Signaling and Its Therapeutic Applications
Current Topics in Medicinal Chemistry New Approach to Immunotherapy Against Organ-specific Autoimmune Diseases with T Cell Receptor and Chemokine Receptor DNA Vaccines
Current Drug Targets - Immune, Endocrine & Metabolic Disorders A Potential Therapeutic Target RNA-binding Protein, Arid5a for the Treatment of Inflammatory Disease Associated with Aberrant Cytokine Expression
Current Pharmaceutical Design Mechanisms Leading to Autoantibody Production: Link Between Inflammation and Autoimmunity
Current Drug Targets - Inflammation & Allergy Effects of Antioxidant Polyphenols on TNF-Alpha-Related Diseases
Current Topics in Medicinal Chemistry Current Status and Future Prospects of Small–molecule Protein–protein Interaction (PPI) Inhibitors of Tumor Necrosis Factor (TNF) and Receptor Activator of NF-κB Ligand (RANKL)
Current Topics in Medicinal Chemistry HSP60 as a Drug Target
Current Pharmaceutical Design Lessons to Learn from Crohn's Disease Clinical Trials: Implications for Ulcerative Colitis
Current Drug Targets CCR2 Antagonists
Current Topics in Medicinal Chemistry The Role of Nitric Oxide in Autoimmune Diseases
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents The Potential of Selected Prostanoid Receptors as Targets in a New Therapeutic Strategy for Allergy and Immune Diseases
Current Drug Safety Inhibitors of ER Aminopeptidase 1 and 2: From Design to Clinical Application
Current Medicinal Chemistry Involvement of IL-1R/TLR Signalling in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis
Current Molecular Medicine Gene Therapy for Immunologic Tolerance: Using Bone Marrow-Derived Cells to Treat Autoimmunity and Hemophilia
Current Stem Cell Research & Therapy Hot topic: Editorial [Therapeutic Potential of Peptide Motifs - Part IV] (Jean Claude Herve)
Current Pharmaceutical Design Molecular Mechanism of the Affinity Interactions between BAFF and Its Peptides by Molecular Simulations
Protein & Peptide Letters Interleukin-7: a key Mediator in T Cell-driven Autoimmunity, Inflammation, and Tissue Destruction
Current Pharmaceutical Design